Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices

Table 3

HCRU during the study period (chart review only).

Variable	Overall (n = 376)	1L pre-October 2016 cohort (n = 97)	1L post-October 2016 cohort (n = 279)	P value	Overall (n = 196)	2L pre-October 2016 cohort (n = 77)	2L post-October 2016 cohort (n = 119)	P value
Patients hospitalized during the study period, n (%)	116 (30.9%)	57 (58.8%)	59 (21.1%)	<0.0001	82 (41.8%)	46 (59.7%)	36 (30.3%)	<0.0001
Patients with ED visits during the study period, n (%)	83 (22.1%)	44 (45.4%)	39 (14.0%)	<0.0001	60 (30.6%)	36 (46.8%)	24 (20.2%)	<0.0001
Patients with surgeries during the study period, n (%)	42 (11.2%)	22 (22.7%)	20 (7.2%)	<0.0001	32 (16.3%)	20 (26.0%)	12 (10.1%)	0.0033
Patients with outpatient visits during the study period, n (%)	297 (79.0%)	83 (85.6%)	214 (76.7%)	0.0649	169 (86.2%)	70 (90.9%)	99 (83.2%)	0.1258
Patients with laboratory procedures during the study period, n (%)	266 (70.7%)	75 (77.3%)	191 (68.5%)	0.0985	154 (78.6%)	65 (84.4%)	89 (74.8%)	0.1087
Patients who received growth factors, n (%)
G-CSF	143 (38.0%)	70 (72.2%)	73 (26.2%)	<0.0001	102 (52.0%)	57 (74.0%)	45 (37.8%)	<0.0001
ESA	18 (4.8%)	8 (8.2%)	10 (3.6%)	0.0639	16 (8.2%)	8 (10.4%)	8 (6.7%)	0.3598
Patients who received dexrazoxane, n (%)	13 (3.5%)	2 (2.1%)	11 (3.9%)	0.5280	9 (4.6%)	2 (2.6%)	7 (5.9%)	0.4869

Variable assessed among patients selected for chart review (n = 211). 1L, first-line; 2L, second-line; ED, emergency department; ESA, erythropoietin-stimulating agents; G-CSF, granulocyte-colony stimulating factor; Min, minimum; Max, maximum; SD, standard deviation.